| Literature DB >> 34208139 |
Maria Tampakaki1,2,3, Mariam-Eleni Oraiopoulou1, Eleftheria Tzamali1, Giorgos Tzedakis1, Takis Makatounakis4, Giannis Zacharakis3, Joseph Papamatheakis4,5, Vangelis Sakkalis1.
Abstract
Glioblastoma is the most malignant brain tumor among adults. Despite multimodality treatment, it remains incurable, mainly because of its extensive heterogeneity and infiltration in the brain parenchyma. Recent evidence indicates dysregulation of the expression of the Promyelocytic Leukemia Protein (PML) in primary Glioblastoma samples. PML is implicated in various ways in cancer biology. In the brain, PML participates in the physiological migration of the neural progenitor cells, which have been hypothesized to serve as the cell of origin of Glioblastoma. The role of PML in Glioblastoma progression has recently gained attention due to its controversial effects in overall Glioblastoma evolution. In this work, we studied the role of PML in Glioblastoma pathophysiology using the U87MG cell line. We genetically modified the cells to conditionally overexpress the PML isoform IV and we focused on its dual role in tumor growth and invasive capacity. Furthermore, we targeted a PML action mediator, the Enhancer of Zeste Homolog 2 (EZH2), via the inhibitory drug DZNeP. We present a combined in vitro-in silico approach, that utilizes both 2D and 3D cultures and cancer-predictive computational algorithms, in order to differentiate and interpret the observed biological results. Our overall findings indicate that PML regulates growth and invasion through distinct cellular mechanisms. In particular, PML overexpression suppresses cell proliferation, while it maintains the invasive capacity of the U87MG Glioblastoma cells and, upon inhibition of the PML-EZH2 pathway, the invasion is drastically eliminated. Our in silico simulations suggest that the underlying mechanism of PML-driven Glioblastoma physiology regulates invasion by differential modulation of the cell-to-cell adhesive and diffusive capacity of the cells. Elucidating further the role of PML in Glioblastoma biology could set PML as a potential molecular biomarker of the tumor progression and its mediated pathway as a therapeutic target, aiming at inhibiting cell growth and potentially clonal evolution regarding their proliferative and/or invasive phenotype within the heterogeneous tumor mass.Entities:
Keywords: Glioblastoma; PML; brain; cancer; in silico modeling; in vitro imaging
Mesh:
Substances:
Year: 2021 PMID: 34208139 PMCID: PMC8230868 DOI: 10.3390/ijms22126289
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Growth evolution of the non-induced U87MG and the PML-OE (U87MG-PML OE) spheroids. (a) Representative bright-field images and confocal z-stacks maximum intensity projection scans of the spheroids in the hanging-drop with and without 30 μM DZNeP treatment (growth; growth + DZNeP, respectively). All images depict the spheroids 3 days after their formation and DZNeP treatment. Green represents DsRed-PML IV, red represents DRAQ7 and cyan represents H2DC-FDA. Scale bar is set at 100 microns. (b) Spatiotemporal growth curves representing the radial expansion of the spheroids in the hanging-drop overtime in control and drug treatment condition with DZNeP at 30 μM concentration.
Figure 2Invasion of the non-induced U87MG and the PML-OE (U87MG-PML OE) spheroids. (a) Representative bright-field images and confocal z-stacks maximum intensity projection scans of the spheroids in the invasive ECM-depended condition with and without 30 μΜ DZNeP treatment (Invasion; Invasion + DZNeP, respectively) 72 h after spheroid formation and DZNeP treatment. Green represents DsRed-PML IV, red represents DRAQ7 and cyan represents H2DC-FDA. Scale bar is set at 100 microns. (b) Spatiotemporal evolution curves representing the radial expansion of the core and the invasive rim of the spheroids within the ECM-depended condition overtime in control and drug treatment condition with DZNeP at 30 μM concentration.
Figure 3In silico simulation curves at the best-fit values of the growth dynamics of the non-invasive non-induced and the PML OE-U87MG spheroids over time. (a) non-induced U87MG and (b) U87MG-PML OE (c) non-induced U87MG spheroids under 30 μM DZNeP treatment and (d) U87MG-PML OE spheroids under 30 μM DZNeP treatment. The in vitro estimates are also shown for comparison.
Summary of the model fitted parameters under study for the non-invasive condition.
| Parameter | U87MG | U87MG-PML OE |
|---|---|---|
| Proliferation Time | 100 h | 160 h |
| Cell Size | 21.5 μm | 21.5 μm |
| Initial Cell Density | 90% | 90% |
| Random Cell Death Rate | 20% of the proliferation time | 20% of the proliferation time |
| DZNeP-Mediated Cell Death Rate | 0.0065 h−1 | 0.0065 h−1 |
Figure 4In silico simulation curves at the best-fit values of the invasive dynamics of the non-induced and the PML OE- U87MG spheroids over time. (a) Non-induced U87MG and (b) U87MG-PML OE; (c) non-induced U87MG spheroids under 30 μM DZNeP treatment and (d) U87MG-PML OE under 30 μM DZNeP treatment. The in vitro estimates are also shown for comparison.
Summary of the model fitted parameters under study for the invasive condition, while the non-invasive parameters are kept constant.
| Parameter | U87MG | U87MG-PML OE |
|---|---|---|
| Diffusion Coefficient | 2.00 × 10−9 cm2/s | 2.00 × 10−9 cm2/s |
| 2:1 | 2:1 | |
| Diffusion Coefficient upon DZNeP Treatment | 2.00 × 10−9 cm2/s | 1.00 × 10−9 cm2/s |
| 1:1 | 1:4 |